In the last three months, 9 analysts have published ratings on Legend Biotech LEGN, offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 4 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.0, a high estimate of $86.00, and a low estimate of $73.00. This current average reflects an increase of 1.13% from the previous average price target of $78.12.
Interpreting Analyst Ratings: A Closer Look
In examining recent analyst actions, we gain insights into how financial experts perceive Legend Biotech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Edward Tenthoff | Piper Sandler | Maintains | Overweight | $78.00 | $78.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $73.00 | $73.00 |
| Rick Bienkowski | Cantor Fitzgerald | Maintains | Overweight | $83.00 | $83.00 |
| Leonid Timashev | RBC Capital | Maintains | Outperform | $86.00 | $86.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $73.00 | $73.00 |
| Leonid Timashev | RBC Capital | Maintains | Outperform | $86.00 | $86.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $73.00 | $73.00 |
| Qize Ding | Redburn Atlantic | Announces | Buy | $86.00 | - |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $73.00 | $73.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Legend Biotech. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Legend Biotech compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Legend Biotech's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into Legend Biotech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Legend Biotech analyst ratings.
Discovering Legend Biotech: A Closer Look
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Legend Biotech's Financial Performance
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Legend Biotech displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 66.86%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Legend Biotech's net margin is impressive, surpassing industry averages. With a net margin of -78.23%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Legend Biotech's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -11.02%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Legend Biotech's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.09%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.31, Legend Biotech adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
